influenza vaccine + pneumococcal polysaccharide vaccine

This entry refers to the co-administration of standard influenza and pneumococcal polysaccharide vaccines as part of a clinical study conducted by the Louisiana State University Health Sciences Center in New Orleans. The study (NCT00135876) was a Phase 2 trial designed to evaluate the feasibility and acceptance of offering these vaccinations to eligible patients in an urban emergency department (ED) setting. The goal was to improve vaccination coverage among high-risk populations, including those aged 50 and older or those with chronic medical conditions. The influenza vaccine component provides active immunization against seasonal influenza A and B viruses, while the pneumococcal polysaccharide vaccine (typically PPSV23) targets *Streptococcus pneumoniae* to prevent pneumonia and other invasive pneumococcal diseases.

Other names

influenza vaccine + pneumococcal vaccineInfluenza and Pneumococcal Vaccine in ED